Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
1 activities
Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hotspots: A Retrospective Study of 82 Patients
Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
1 activities
Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML
Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
1 activities
Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission
Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
1 activities
Impact of Cytogenetic Response on Long-Term Survival in Acute Myeloid Leukemia: A Retrospective Cohort Study
Incidence, Risk Factors, and Outcomes of Candida Bloodstream Infections in Hematological and Oncological Patients
1 activities
Incidence, Risk Factors, and Outcomes of Candida Bloodstream Infections in Hematological and Oncological Patients
Investigation of Epidemiological Factors and Site of Primary Tumor on the Development of AML As Second Primary Cancer after Diagnosis of Myeloid Sarcoma and the Impact of Chemotherapy on Overall Survival
1 activities
Investigation of Epidemiological Factors and Site of Primary Tumor on the Development of AML As Second Primary Cancer after Diagnosis of Myeloid Sarcoma and the Impact of Chemotherapy on Overall Survival
NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
1 activities
NCAM1 (CD56) As a Predictor of Response to Standard Intensive Induction in Newly Diagnosed Acute Myeloid Leukemia
Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML – a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax
1 activities
Outcomes By Frailty in IC-Ineligible Newly Diagnosed AML – a Real-World Evidence Comparison By Treatment with Hypomethylating Agents + Ivosidenib or Venetoclax
Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
1 activities
Outcomes of Blast-Phase MPN and JAK2, MPL, and CALR Mutated de Novo AML Compared to AML with Wild-Type JAK2, MPL, and CALR Genes: A Propensity Score-Adjusted Cohort Study
Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Response to Intensive Induction Chemotherapy, Suggesting Futility of Mid-Cycle Bone Marrow Biopsy and Caution When Considering Re-Induction
1 activities
Patients with AML and an IDH2-R172 Mutation Exhibit a Unique Response to Intensive Induction Chemotherapy, Suggesting Futility of Mid-Cycle Bone Marrow Biopsy and Caution When Considering Re-Induction
Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
1 activities
Predictors of Relapse and Post-Relapse Outcomes in Patients with Newly-Diagnosed Acute Myeloid Leukemia Treated with Venetoclax + Hypomethylating Agent
Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
1 activities
Salvage Reinduction Chemotherapy Versus Alternative Regimens after Failed AML Intensive Induction Regimen, a Single Center Experience
The Burden of Cardiovascular-Related Mortality in Early-Onset Acute Myeloid Leukemia
1 activities
The Burden of Cardiovascular-Related Mortality in Early-Onset Acute Myeloid Leukemia
The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia
1 activities
The Impact of Weight Loss Grading Scale, a Measure of Cancer Cachexia, on Clinical Outcomes in Patients with Acute Myeloid Leukemia
Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease
1 activities
Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease
Trends in Acute Myeloid Leukemia (AML) Hospitalization: Incidence, Mortality, Length of Stay, and Financial Burden from 2011 to 2018
1 activities
Trends in Acute Myeloid Leukemia (AML) Hospitalization: Incidence, Mortality, Length of Stay, and Financial Burden from 2011 to 2018
Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By t...
1 activities
Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria.